-
1
-
-
33646375742
-
Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: An update
-
M. Kaufmann, G.N. Hortobagyi, A. Goldhirsch, S. Scholl, A. Makris, P. Valagussa, J.U. Blohmer, W. Eiermann, R. Jackesz, W. Jonat, A. Lebeau, S. Loibl, W. Miller, S. Seeber, V. Semiglazov, R. Smith, R. Souchon, V. Stearns, M. Untch, G. von Minckwitz, Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update, J. Clin. Oncol. 24 (12) (2006) 1940-1949.
-
(2006)
J. Clin. Oncol.
, vol.24
, Issue.12
, pp. 1940-1949
-
-
Kaufmann, M.1
Hortobagyi, G.N.2
Goldhirsch, A.3
Scholl, S.4
Makris, A.5
Valagussa, P.6
Blohmer, J.U.7
Eiermann, W.8
Jackesz, R.9
Jonat, W.10
Lebeau, A.11
Loibl, S.12
Miller, W.13
Seeber, S.14
Semiglazov, V.15
Smith, R.16
Souchon, R.17
Stearns, V.18
Untch, M.19
Von Minckwitz, G.20
more..
-
2
-
-
0034913582
-
Letrozole as primary medical therapy for locally advanced and large operable breast cancer
-
J.M. Dixon, C.D. Love, C.O. Bellamy, D.A. Cameron, R.C. Leonard, H. Smith, W.R. Miller, Letrozole as primary medical therapy for locally advanced and large operable breast cancer, Breast Cancer Res. Treat. 66 (3) (2001) 191-199.
-
(2001)
Breast Cancer Res. Treat.
, vol.66
, Issue.3
, pp. 191-199
-
-
Dixon, J.M.1
Love, C.D.2
Bellamy, C.O.3
Cameron, D.A.4
Leonard, R.C.5
Smith, H.6
Miller, W.R.7
-
3
-
-
0242541296
-
Neoadjuvant tamoxifen and aromatase inhibitors: Comparisons and clinical outcomes
-
J.M. Dixon, J. Jackson, L. Renshaw, W.R. Miller, Neoadjuvant tamoxifen and aromatase inhibitors: comparisons and clinical outcomes, J. Steroid. Biochem. Mol. Biol. 86 (3-5) (2003) 295-299.
-
(2003)
J. Steroid. Biochem. Mol. Biol.
, vol.86
, Issue.3-5
, pp. 295-299
-
-
Dixon, J.M.1
Jackson, J.2
Renshaw, L.3
Miller, W.R.4
-
4
-
-
0242575827
-
An integrated view of aromatase and its inhibition
-
W.R. Miller, T.J. Anderson, D.B. Evans, A. Krause, G. Hampton, J.M. Dixon, An integrated view of aromatase and its inhibition, J. Steroid Biochem. Mol. Biol. 86 (2003) 413-421.
-
(2003)
J. Steroid Biochem. Mol. Biol.
, vol.86
, pp. 413-421
-
-
Miller, W.R.1
Anderson, T.J.2
Evans, D.B.3
Krause, A.4
Hampton, G.5
Dixon, J.M.6
-
5
-
-
23744497498
-
Aromatase inhibitors: Cellular and molecular effects
-
W.R. Miller, T.J. Anderson, S. White, A. Larionov, J. Murray, D. Evans, A. Krause, J.M. Dixon, Aromatase inhibitors: cellular and molecular effects, J. Steroid Biochem. Mol. Biol. 95 (2005) (2005) 83-89.
-
(2005)
J. Steroid Biochem. Mol. Biol.
, vol.95
, Issue.2005
, pp. 83-89
-
-
Miller, W.R.1
Anderson, T.J.2
White, S.3
Larionov, A.4
Murray, J.5
Evans, D.6
Krause, A.7
Dixon, J.M.8
-
6
-
-
0035692576
-
Letrozole Neo-Adjuvant Breast Cancer Study Group, Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized doubleblind multicenter study
-
W. Eiermann, S. Paepke, J. Appfelstaedt, A. Llombart-Cussac, J. Eremin, J. Vinholes, L. Mauriac, M. Ellis, M. Lassus, H.A. Chaudri-Ross, M. Dugan, M. Borgs, Letrozole Neo-Adjuvant Breast Cancer Study Group, Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized doubleblind multicenter study, Ann. Oncol. 12 (11) (2001) 1527-1532.
-
(2001)
Ann. Oncol.
, vol.12
, Issue.11
, pp. 1527-1532
-
-
Eiermann, W.1
Paepke, S.2
Appfelstaedt, J.3
Llombart-Cussac, A.4
Eremin, J.5
Vinholes, J.6
Mauriac, L.7
Ellis, M.8
Lassus, M.9
Chaudri-Ross, H.A.10
Dugan, M.11
Borgs, M.12
-
7
-
-
24644490871
-
Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: The Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial
-
IMPACT Trialists Group
-
I.E. Smith, M. Dowsett, S.R. Ebbs, J.M. Dixon, A. Skene, J.U. Blohmer, S.E. Ashley, S. Francis, I. Boeddinghaus, G. Walsh, IMPACT Trialists Group, Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial, J. Clin. Oncol. 23 (22) (2005) 5108-5116.
-
(2005)
J. Clin. Oncol.
, vol.23
, Issue.22
, pp. 5108-5116
-
-
Smith, I.E.1
Dowsett, M.2
Ebbs, S.R.3
Dixon, J.M.4
Skene, A.5
Blohmer, J.U.6
Ashley, S.E.7
Francis, S.8
Boeddinghaus, I.9
Walsh, G.10
-
8
-
-
0033008206
-
Lessons from the use of aromatase inhibitors in the neoadjuvant setting
-
J.M. Dixon, C.D.B. Love, L. Renshaw, et al., Lessons from the use of aromatase inhibitors in the neoadjuvant setting, Endocr. Relat. Cancer 6 (1999) 227-230.
-
(1999)
Endocr. Relat. Cancer
, vol.6
, pp. 227-230
-
-
Dixon, J.M.1
Love, C.D.B.2
Renshaw, L.3
-
9
-
-
1542294791
-
Pathology of breast cancer following neoadjuvant therapy
-
W.R. Miller, J.N. Ingle (Eds.), Marcel Dekker, New York, USA
-
H. Sasano, T. Suzuki, T. Moriya, Pathology of breast cancer following neoadjuvant therapy, in: W.R. Miller, J.N. Ingle (Eds.), Endocrine Therapy in Breast Cancer, Marcel Dekker, New York, USA, 2002, pp. 213-222.
-
(2002)
Endocrine Therapy in Breast Cancer
, pp. 213-222
-
-
Sasano, H.1
Suzuki, T.2
Moriya, T.3
-
10
-
-
0345314101
-
Pathological features of breast cancer response following neoadjuvant treatment with either letrozole or tamoxifen
-
W.R. Miller, J.M. Dixon, L. Macfarlane, et al., Pathological features of breast cancer response following neoadjuvant treatment with either letrozole or tamoxifen, Eur. J. Cancer 39 (4) (2002) 462-468.
-
(2002)
Eur. J. Cancer
, vol.39
, Issue.4
, pp. 462-468
-
-
Miller, W.R.1
Dixon, J.M.2
MacFarlane, L.3
-
11
-
-
0037194407
-
Effect of neoadjuvant treatment with anastrozole on tumour histology in postmenopausal women with large operable breast cancer
-
T.J. Anderson, J.M. Dixon, M. Stuart, et al., Effect of neoadjuvant treatment with anastrozole on tumour histology in postmenopausal women with large operable breast cancer, Br. J. Cancer 87 (2002) 334-338.
-
(2002)
Br. J. Cancer
, vol.87
, pp. 334-338
-
-
Anderson, T.J.1
Dixon, J.M.2
Stuart, M.3
-
12
-
-
0035717497
-
Biological and clinical effects of aromatase inhibitors in neoadjuvant therapy
-
W.R. Miller, J.M. Dixon, D.A. Cameron, T.J. Anderson, Biological and clinical effects of aromatase inhibitors in neoadjuvant therapy, J. Steroid Biochem.Mol. Biol. 79 (1-5) (2001) 103-107.
-
(2001)
J. Steroid Biochem.Mol. Biol.
, vol.79
, Issue.1-5
, pp. 103-107
-
-
Miller, W.R.1
Dixon, J.M.2
Cameron, D.A.3
Anderson, T.J.4
-
13
-
-
33645735920
-
Proliferation, steroid receptors and clinical/pathological response in breast cancer treated with letrozole
-
W.R. Miller, S. White, J.M. Dixon, J. Murray, L. Renshaw, T.J. Anderson, Proliferation, steroid receptors and clinical/pathological response in breast cancer treated with letrozole, Br. J. Cancer 94 (2006) 1051-1056.
-
(2006)
Br. J. Cancer
, vol.94
, pp. 1051-1056
-
-
Miller, W.R.1
White, S.2
Dixon, J.M.3
Murray, J.4
Renshaw, L.5
Anderson, T.J.6
-
14
-
-
19944429855
-
IMPACT Trialists: Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival
-
M. Dowsett, I.E. Smith, S.R. Ebbs, J.M. Dixon, A. Skene, C. Griffith, I. Boeddinghaus, J. Salter, S. Detre, M. Hills, S. Ashley, S. Francis, G. Walsh, IMPACT Trialists: short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival, Clin. Cancer Res. 11 (2 Pt 2) (2005) 951s-958s.
-
(2005)
Clin. Cancer Res.
, vol.11
, Issue.2 PART 2
-
-
Dowsett, M.1
Smith, I.E.2
Ebbs, S.R.3
Dixon, J.M.4
Skene, A.5
Griffith, C.6
Boeddinghaus, I.7
Salter, J.8
Detre, S.9
Hills, M.10
Ashley, S.11
Francis, S.12
Walsh, G.13
-
15
-
-
23744448408
-
Clinical and biomarker endpoint analysis in neoadjuvant endocrine therapy trials
-
Y. Tao, A. Klause, A. Vickers, K. Bae, M. Ellis, Clinical and biomarker endpoint analysis in neoadjuvant endocrine therapy trials, J. Steroid Biochem. Mol. Biol. 95 (1-5) (2005) 91-95.
-
(2005)
J. Steroid Biochem. Mol. Biol.
, vol.95
, Issue.1-5
, pp. 91-95
-
-
Tao, Y.1
Klause, A.2
Vickers, A.3
Bae, K.4
Ellis, M.5
-
16
-
-
0035576786
-
HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer
-
M. Dowsett, C. Harper-Wynne, I. Boeddinghaus, J. Salter, M. Hills, M. Dixon, S. Ebbs, G. Gui, N. Sacks, I. Smith, HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer, Cancer Res. 61 (23) (2001) 8452-8458.
-
(2001)
Cancer Res.
, vol.61
, Issue.23
, pp. 8452-8458
-
-
Dowsett, M.1
Harper-Wynne, C.2
Boeddinghaus, I.3
Salter, J.4
Hills, M.5
Dixon, M.6
Ebbs, S.7
Gui, G.8
Sacks, N.9
Smith, I.10
-
17
-
-
9644262523
-
Anastrozole demonstrates clinical and biological effectiveness in oestrogen receptor-positive breast cancers, irrespective of the erbB2 status
-
J.M. Dixon, J. Jackson, M. Hills, L. Renshaw, D.A. Cameron, T.J. Anderson, W.R. Miller, M. Dowsett, Anastrozole demonstrates clinical and biological effectiveness in oestrogen receptor-positive breast cancers, irrespective of the erbB2 status, Eur. J. Cancer 40 (18) (2004) 2742-2747.
-
(2004)
Eur. J. Cancer
, vol.40
, Issue.18
, pp. 2742-2747
-
-
Dixon, J.M.1
Jackson, J.2
Hills, M.3
Renshaw, L.4
Cameron, D.A.5
Anderson, T.J.6
Miller, W.R.7
Dowsett, M.8
-
18
-
-
25844433766
-
Growth factor signalling in clinical breast cancer and its impact on response to conventional therapies: The Edinburgh experience
-
W.R. Miller, T.J. Anderson, S. White, D. Evans, A. Krause, J.M. Dixon, Growth factor signalling in clinical breast cancer and its impact on response to conventional therapies: the Edinburgh experience, Endocr. Relat. Cancer 12 (Suppl 1) (2005) S119-123.
-
(2005)
Endocr. Relat. Cancer
, vol.12
, Issue.SUPPL. 1
-
-
Miller, W.R.1
Anderson, T.J.2
White, S.3
Evans, D.4
Krause, A.5
Dixon, J.M.6
-
19
-
-
33745988573
-
Estrogen-independent proliferation is present in estrogen-receptor HER2- positive primary breast cancer after neoadjuvant letrozole
-
M.J. Ellis, Y. Tao, O. Young, S. White, A.D. Proia, J. Murray, L. Renshaw, D. Faratian, J. Thomas, M. Dowsett, A. Krause, D.B. Evans, W.R. Miller, J.M. Dixon, Estrogen-independent proliferation is present in estrogen-receptor HER2- positive primary breast cancer after neoadjuvant letrozole, J. Clin. Oncol. 24 (19) (2006) 3019-3025.
-
(2006)
J. Clin. Oncol.
, vol.24
, Issue.19
, pp. 3019-3025
-
-
Ellis, M.J.1
Tao, Y.2
Young, O.3
White, S.4
Proia, A.D.5
Murray, J.6
Renshaw, L.7
Faratian, D.8
Thomas, J.9
Dowsett, M.10
Krause, A.11
Evans, D.B.12
Miller, W.R.13
Dixon, J.M.14
-
20
-
-
0035884620
-
Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB- 1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: Evidence from a phase III randomized trial
-
M.J. Ellis, A. Coop, B. Singh, L. Mauriac, A. Llombert-Cussac, F. Janicke, W.R. Miller, D.B. Evans, D. Dugan, C. Brady, E. Quebe-Fehling, M. Borgs, Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB- 1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial, J. Clin. Oncol. 19 (No 18) (2001) 3808-3816.
-
(2001)
J. Clin. Oncol.
, vol.19
, Issue.18
, pp. 3808-3816
-
-
Ellis, M.J.1
Coop, A.2
Singh, B.3
Mauriac, L.4
Llombert-Cussac, A.5
Janicke, F.6
Miller, W.R.7
Evans, D.B.8
Dugan, D.9
Brady, C.10
Quebe-Fehling, E.11
Borgs, M.12
-
21
-
-
34548445351
-
Molecular response to aromatase inhibitor treatment in primary breast cancer
-
A Mackay, A. Urruticoechea, J.M. Dixon, T. Dexter, K. Fenwick, A. Ashworth, S. Drury, A. Larionov, O. Young, S. White, W.R. Miller, D.B. Evans, M. Dowsett, Molecular response to aromatase inhibitor treatment in primary breast cancer, Breast Cancer Res. 9 (3) (2007) R37.
-
(2007)
Breast Cancer Res.
, vol.9
, Issue.3
-
-
MacKay, A.1
Urruticoechea, A.2
Dixon, J.M.3
Dexter, T.4
Fenwick, K.5
Ashworth, A.6
Drury, S.7
Larionov, A.8
Young, O.9
White, S.10
Miller, W.R.11
Evans, D.B.12
Dowsett, M.13
-
22
-
-
34548433015
-
Aromatase inhibitors-gene discovery
-
W.R. Miller, A. Larionov, L. Renshaw, T.J. Anderson, S. White, G. Hampton, J.R. Walker, S. Ho, A. Krause, D.B. Evans, J.M. Dixon, Aromatase inhibitors-gene discovery, J. Steroid Biochem. Mol. Biol. 106 (1-5) (2007) 130-142.
-
(2007)
J. Steroid Biochem. Mol. Biol.
, vol.106
, Issue.1-5
, pp. 130-142
-
-
Miller, W.R.1
Larionov, A.2
Renshaw, L.3
Anderson, T.J.4
White, S.5
Hampton, G.6
Walker, J.R.7
Ho, S.8
Krause, A.9
Evans, D.B.10
Dixon, J.M.11
-
23
-
-
34648858600
-
Changes in breast cancer transcriptional profiles after treatment with the aromatase inhibitor, letrozole
-
W.R. Miller, A.A. Larionov, L. Renshaw, T.J. Anderson, S. White, J. Murray, E. Murray, G. Hampton, J.R. Walker, S. Ho, A. Krause, D.B. Evans, J.M. Dixon, Changes in breast cancer transcriptional profiles after treatment with the aromatase inhibitor, letrozole, Pharmacogenet. Genomics 17 (10) (2007) 813-826.
-
(2007)
Pharmacogenet. Genomics
, vol.17
, Issue.10
, pp. 813-826
-
-
Miller, W.R.1
Larionov, A.A.2
Renshaw, L.3
Anderson, T.J.4
White, S.5
Murray, J.6
Murray, E.7
Hampton, G.8
Walker, J.R.9
Ho, S.10
Krause, A.11
Evans, D.B.12
Dixon, J.M.13
-
24
-
-
38749100194
-
Predicting response and resistance to endocrine therapy: Profiling patients on aromatase inhibitors
-
W.R. Miller, A. Larionov, T.J. Anderson, J.R. Walker, A. Krause, D.B. Evans, J.M. Dixon, Predicting response and resistance to endocrine therapy: profiling patients on aromatase inhibitors, Cancer 112 (S3) (2007) 689-694.
-
(2007)
Cancer
, vol.112 S3
, pp. 689-694
-
-
Miller, W.R.1
Larionov, A.2
Anderson, T.J.3
Walker, J.R.4
Krause, A.5
Evans, D.B.6
Dixon, J.M.7
-
25
-
-
63049137792
-
Gene expression profiles differentiating between breast cancers clinically responsive or resistant to letrozole
-
W.R. Miller, A. Larionov, L. Renshaw, T.J. Anderson, J.R. Walker, A. Krause, T. Singh, D.B. Evans, J.M. Dixon, Gene expression profiles differentiating between breast cancers clinically responsive or resistant to letrozole, J. Clin. Oncol. 27 (9) (2009) 1382-1387.
-
(2009)
J. Clin. Oncol.
, vol.27
, Issue.9
, pp. 1382-1387
-
-
Miller, W.R.1
Larionov, A.2
Renshaw, L.3
Anderson, T.J.4
Walker, J.R.5
Krause, A.6
Singh, T.7
Evans, D.B.8
Dixon, J.M.9
-
26
-
-
60749126579
-
Identification and mechanisms of endocrine resistance
-
W.R. Miller, Identification and mechanisms of endocrine resistance, Breast Cancer Res. 10 (Suppl 4) (2008) S19.
-
(2008)
Breast Cancer Res.
, vol.10
, Issue.SUPPL. 4
-
-
Miller, W.R.1
|